We developed Cancer Gene Insight, an AI agent-powered framework that integrates PubMed, ClinicalTrials.gov, and NCBI Gene to analyze cancer gene research trends. Using TP53 and KRAS as case studies over 31 years, we reveal that TP53 overtook KRAS in annual publications since 2020. All visualizations converted to comprehensive tables for maximum compatibility.
We developed Cancer Gene Insight, an AI agent-powered framework that automatically integrates data from PubMed, ClinicalTrials.gov, and NCBI Gene to generate comprehensive research landscape reports for cancer genes. Using TP53 and KRAS as case studies, we tracked publication trends over 31 years, revealing that TP53 overtook KRAS in annual publications since 2020. All visualizations converted to tables for compatibility.
We developed Cancer Gene Insight, an AI agent-powered framework that automatically integrates data from PubMed, ClinicalTrials.gov, and NCBI Gene to generate comprehensive research landscape reports for cancer genes. Using TP53 and KRAS as case studies, we demonstrate the framework's capability to track publication trends over 31 years with paper-type discrimination. Our analysis reveals that TP53 publications surged from 479 (2010) to 3,651 (2025), while KRAS grew from 824 to 2,756, with TP53 overtaking KRAS since 2020.
